R&D Facilities

The quality and safety of our products are our top priorities.

We understand that facility locations can benefit our patients, providers and stakeholders tremendously. By developing and manufacturing the majority of our products in our U.S. and Swiss facilities, we can ensure that our product supplies are always manufactured to the highest standards.

All Ingenus facilities are in compliance with quality, safety, and environmental standards as mandated by state and federal governments and regulators.

  • Ingenus’ New Jersey-based research & development facility specializes in the development of solid orals (IR, MR, SL, and Films), topicals (ointments, creams, lotions, gels, powders, foams, and sprays), transdermal patches (Hydrogel & Matrix), injectables (solutions, lyophilized, and suspensions), and nasal sprays.
  • Our preformulation studies emphasize polymorphic screening and stabilization, salt screening, solid state and materials characterization, excipient compatibility, stability studies using HPLC, TGA, DSC, DVS (absorption/desorption), XRPD, diffusion, and particle size analysis.
  • USFDA registered and FDA approved full-fledged development, analytical, quality control, and stability testing lab.

Ingenus’ India-based research and development facility, Ricon Pharma, has founded its business focus and mission on the research of innovative concepts in pharmaceutical product and process development using advanced manufacturing technologies and Quality by Design (QbD) principles for the 21st century. These products and processes include:

  • Preformulation: Pre-clinical studies using state-of-the art instruments.
  • Formulation Development: Oral solid dosages, topicals, transdermals, liquids and parenterals.
  • Technology: Systems for drug delivery, platform technologies, continuous processing, PAT and advanced process controls, automation, and patents and IP.
  • Regulatory Submissions: CMC section development, 505 (b)(2) submissions (NDA), orphan drug submissions (NDA), suitability petitions (ANDA), Paragraph IV, NDA and ANDA submissions, and FDA Pre-IND and Pre-NDA meetings.
  • Manufacturing: Process development for lead time reduction, step change productivity improvement, Continuous Process Verification (CQV) and alternate processing.
  • Automation/PAT Advance Process Control/Modeling for Continuous Improvement: Automation, process analytical technology (PAT) to real-time release (RTR), process control, process modeling, process mapping and data mining.